GO:0016925 protein sumoylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016925 protein sumoylation is the covalent conjugation of a SUMO protein to a target lysine via an isopeptide bond.
• Sumoylation is a reversible post-translational modification that controls protein stability, localization, and interactions.
• Dysregulated sumoylation is linked to cancer, liver disease, airway inflammation, and viral pathogenesis.
• Core enzymes include SUMO-activating E1 (SAE1/SAE2), conjugating E2 (UBE2I), and multiple E3 ligases such as PIAS and TRIM28.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect sumoylation causality.
• Therapeutic strategies targeting sumoylation are under active investigation for oncology and inflammatory diseases.
Description
Protein sumoylation (GO:0016925) is a conserved post-translational modification in which a small ubiquitin-related modifier (SUMO) is covalently attached to a target protein through an isopeptide bond between the SUMO C-terminus and the epsilon-amino group of a lysine residue. This process is reversible and dynamically regulates protein function without directly causing degradation, distinguishing it from ubiquitination. Sumoylation is essential for normal cellular physiology and is implicated in a broad range of human diseases, including cancer, liver disease, and inflammatory airway disorders. Because sumoylation can alter protein-protein interactions, subcellular localization, and transcriptional activity, it has become a major focus for researchers seeking to understand disease mechanisms and identify therapeutic targets. Recent studies have also highlighted its role in viral pathogenesis, such as SARS-CoV-2 nucleocapsid SUMOylation enhancing virulence. Consequently, robust experimental models and validated reagents are critical for investigating sumoylation in health and disease.
protein sumoylation At A Glance
| GO ID | GO:0016925 |
|---|---|
| GO term | protein sumoylation |
| Ontology | biological_process |
| Synonym | protein sumolation; small ubiquitin-related protein 1 conjugation; Smt3p-protein conjugation; Smt3-protein conjugation; SUMO-protein conjugation; sumoylation |
| Major function | Covalent attachment of SUMO to target lysine residues, regulating protein stability, localization, and interactions |
| Key enzymes | SUMO-activating enzyme E1 (SAE1/SAE2), conjugating enzyme E2 (UBE2I), and E3 ligases such as PIAS and TRIM28 |
| Reversibility | Deconjugation by SENP family proteases |
| Disease relevance | Cancer, liver disease, allergic airway inflammation, viral infections |
What Is GO:0016925?
GO:0016925 protein sumoylation is defined as the process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxy-terminus of SUMO and an epsilon-amino group of a lysine residue on the target protein. This modification is reversible and does not necessarily lead to proteasomal degradation, unlike ubiquitination.
Why Is protein sumoylation Important in Cell Biology?
Protein sumoylation is a fundamental regulatory mechanism that controls diverse cellular processes, including transcription, DNA repair, cell cycle progression, and stress responses. Its dysregulation contributes to cancer, metabolic liver disease, inflammatory airway diseases, and viral pathogenesis. Because sumoylation can be targeted pharmacologically, it represents a promising therapeutic avenue.
• Regulates protein-protein interactions and subcellular localization.
• Controls transcription factor activity and gene expression programs.
• Modulates DNA damage repair and genome stability.
• Implicated in cancer initiation and progression through altered protein homeostasis.
• Plays a role in liver disease pathogenesis, including steatosis and hepatocellular carcinoma.
• Contributes to allergic airway inflammation via Rho-associated protein kinase 2 sumoylation.
• Enhances SARS-CoV-2 virulence through nucleocapsid protein SUMOylation.
• Provides a reversible switch for cellular stress responses.
• Offers a target for therapeutic intervention in oncology and inflammatory diseases.
• Essential for normal development and tissue homeostasis.
What Happens During protein sumoylation?
Activation by E1 enzyme
In simple terms: SUMO is first activated by an enzyme that uses ATP to prepare it for attachment.
The SUMO-activating enzyme E1 (a heterodimer of SAE1 and SAE2) catalyzes the ATP-dependent formation of a thioester bond between the SUMO C-terminus and a cysteine residue in the E1 active site.
Conjugation by E2 enzyme
In simple terms: The activated SUMO is transferred to a carrier enzyme that brings it to the target protein.
The SUMO-conjugating enzyme E2 (UBE2I, also known as UBC9) receives SUMO from E1 via a transesterification reaction, forming a thioester intermediate.
Ligation by E3 ligases
In simple terms: Helper proteins called E3 ligases help attach SUMO to the correct target lysine.
E3 ligases, such as PIAS family proteins and TRIM28, facilitate the transfer of SUMO from UBE2I to the epsilon-amino group of a lysine residue on the substrate, forming an isopeptide bond.
Substrate recognition and specificity
In simple terms: Only certain proteins get sumoylated because the target lysine is recognized in a specific context.
Substrate specificity is often determined by a consensus motif (psi-K-x-E) or by interaction with E3 ligases that recruit specific targets. For example, TRIM28 mediates SUMOylation of the SARS-CoV-2 nucleocapsid protein.
Deconjugation by SENP proteases
In simple terms: SUMO can be removed by enzymes called SENPs, making the modification reversible.
Sentrin-specific proteases (SENPs) cleave the isopeptide bond, releasing SUMO from the target protein and recycling it for another round of conjugation.
Key Genes Involved in GO:0016925 protein sumoylation
The following genes and proteins are central to protein sumoylation, including enzymes, substrates, and regulatory factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SUMO1 | Small ubiquitin-related modifier 1 | Primary SUMO paralog; conjugated to target proteins |
| SUMO2 | Small ubiquitin-related modifier 2 | Stress-induced sumoylation |
| SUMO3 | Small ubiquitin-related modifier 3 | Similar to SUMO2; regulates stress responses |
| SAE1 | SUMO-activating enzyme E1 subunit 1 | Required for SUMO activation |
| SAE2 | SUMO-activating enzyme E1 subunit 2 | Required for SUMO activation |
| UBE2I | SUMO-conjugating enzyme E2 | Central conjugating enzyme |
| PIAS1 | E3 SUMO-protein ligase | Promotes sumoylation of specific substrates |
| PIAS2 | E3 SUMO-protein ligase | Regulates transcription factors |
| PIAS3 | E3 SUMO-protein ligase | Modulates STAT signaling |
| PIAS4 | E3 SUMO-protein ligase | DNA repair and genome stability |
| TRIM28 | E3 SUMO-protein ligase | Mediates SARS-CoV-2 nucleocapsid SUMOylation |
| SENP1 | SUMO-specific protease | Deconjugates SUMO from targets |
| SENP2 | SUMO-specific protease | Regulates sumoylation dynamics |
| SENP3 | SUMO-specific protease | Stress-responsive deconjugation |
| Rho-associated protein kinase 2 (ROCK2) | Substrate | Sumoylation induces goblet cell metaplasia in allergic airways |
| EPAC1 | Substrate | SUMOylation promotes cAMP-independent activation |
| SARS-CoV-2 nucleocapsid | Viral substrate | SUMOylation enhances virulence |
How Is protein sumoylation Regulated?
Protein sumoylation is dynamically regulated by the balance between conjugating enzymes (E1, E2, E3 ligases) and deconjugating SENP proteases. Cellular stress, such as heat shock or oxidative stress, can increase global sumoylation levels. Additionally, sumoylation can be regulated by phosphorylation and other post-translational modifications that affect enzyme activity or substrate accessibility. In disease contexts, aberrant sumoylation is associated with altered expression or activity of these regulatory components.
protein sumoylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPAC1 | Cancer signaling | Knockout or point-mutation cell lines |
| ROCK2 | Allergic airway inflammation | Knock-in or overexpression models |
| TRIM28 | SARS-CoV-2 virulence | Knockout or knockdown in viral infection models |
| SUMO1/2/3 | Liver disease | Knockout or overexpression in hepatocytes |
| SENP1 | Cancer | Knockout or point-mutation models |
Cancer
Dysregulated protein sumoylation contributes to cancer by altering the stability and activity of oncoproteins and tumor suppressors. For example, SUMOylation of EPAC1 promotes cAMP-independent activation, which may influence cancer cell signaling. Targeting sumoylation pathways is being explored as a therapeutic strategy in oncology.
Liver disease
Abnormal protein SUMOylation has been implicated in the pathogenesis of liver diseases, including non-alcoholic fatty liver disease and hepatocellular carcinoma. Modulating sumoylation may offer novel therapeutic targets for liver disease.
Allergic airway inflammation
SUMOylation of Rho-associated protein kinase 2 (ROCK2) induces goblet cell metaplasia in allergic airways, contributing to mucus overproduction and airway remodeling. This highlights sumoylation as a potential target for asthma and other allergic diseases.
Viral infections
TRIM28-mediated SUMOylation of the SARS-CoV-2 nucleocapsid protein enhances viral virulence, suggesting that sumoylation inhibitors could be repurposed as antiviral agents.
From protein sumoylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SUMO1 affect target protein stability? | SUMO1 knockout cell line |
| Does a specific lysine mutation abolish sumoylation? | Point-mutation knock-in of target gene |
| Does SUMOylation of ROCK2 induce goblet cell metaplasia? | Knock-in of SUMOylation-deficient ROCK2 |
| Does overexpression of EPAC1 increase cAMP-independent activation? | Overexpression cell model |
| Does TRIM28 mediate SARS-CoV-2 nucleocapsid SUMOylation? | TRIM28 knockout cells infected with SARS-CoV-2 |
| Can SENP1 inhibition alter cancer cell proliferation? | SENP1 knockout or point-mutation models |
How to Study the protein sumoylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunoblotting with anti-SUMO | Global and substrate-specific sumoylation | Detecting changes in sumoylation levels |
| Mass spectrometry | Sumoylated proteins and sites | Proteome-wide substrate identification |
| Co-immunoprecipitation | Protein-protein interactions | Assessing sumoylation-dependent interactions |
| Subcellular fractionation | Protein localization | Determining effect of sumoylation on localization |
| Reporter assays | Transcriptional activity | Measuring sumoylation effects on transcription factors |
| CRISPR knockout screens | Gene essentiality and pathway components | Identifying regulators of sumoylation |
| Site-directed mutagenesis | Specific lysine requirement | Mapping sumoylation sites |
| SENP protease assays | Deconjugation activity | Measuring reversibility of sumoylation |
Detection of sumoylation by immunoblotting
Sumoylation can be detected by immunoblotting with anti-SUMO antibodies, which reveal a characteristic ladder of conjugated proteins. This method is widely used to assess global sumoylation levels and specific substrate modification.
Proteomic identification of SUMO substrates
Mass spectrometry-based proteomics, often using SUMO affinity purification, enables unbiased identification of sumoylated proteins and their modification sites. This approach has expanded the catalog of SUMO targets in health and disease.
Functional assays for sumoylation
Reporter assays, co-immunoprecipitation, and subcellular fractionation can determine how sumoylation affects protein interactions, localization, and activity. For example, sumoylation of EPAC1 was shown to promote cAMP-independent activation using such assays.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that regulate sumoylation or that are required for sumoylation-mediated phenotypes. These screens are powerful for discovering novel components of the sumoylation pathway.
How CRISPR Can Be Used to Study GO:0016925 protein sumoylation
Knockout
CRISPR knockout of SUMO pathway genes (e.g., UBE2I, SAE1, SAE2) or specific E3 ligases can abolish sumoylation of target proteins, enabling loss-of-function studies. Knockout cell models are essential to determine whether a candidate gene is causally involved in a sumoylation-dependent phenotype.
Point Mutation
Introducing point mutations at the acceptor lysine of a target protein (e.g., K-to-R) via CRISPR can specifically prevent its sumoylation without affecting other functions. This approach is critical to distinguish sumoylation-dependent from independent roles.
Knock-in
Knock-in of tagged SUMO (e.g., His-SUMO or GFP-SUMO) allows affinity purification and imaging of sumoylated proteins in their native context. Tagged knock-in models facilitate proteomic and live-cell imaging studies.
Overexpression
CRISPR activation or cDNA overexpression of SUMO or E3 ligases can enhance sumoylation of specific targets, mimicking disease-associated gain-of-function states. Overexpression models are useful for studying the consequences of hyper-sumoylation.
How EDITGENE Supports protein sumoylation Research
Researchers studying protein sumoylation-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer cell proliferation or inflammatory signaling. EDITGENE provides custom CRISPR cell models and screening services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for protein sumoylation research.
Frequently Asked Questions About protein sumoylation
What is protein sumoylation?
Protein sumoylation (GO:0016925) is the covalent attachment of a SUMO protein to a target lysine residue via an isopeptide bond, regulating protein function.
What genes are involved in protein sumoylation?
Key genes include SUMO1/2/3, SAE1, SAE2, UBE2I, PIAS family E3 ligases, TRIM28, and SENP proteases.
How is protein sumoylation different from ubiquitination?
Sumoylation typically does not lead to proteasomal degradation but instead modulates protein interactions, localization, and activity, whereas ubiquitination often targets proteins for degradation.
What diseases are linked to abnormal protein sumoylation?
Dysregulated sumoylation is associated with cancer, liver disease, allergic airway inflammation, and viral infections such as SARS-CoV-2.
What enzymes catalyze protein sumoylation?
Sumoylation is catalyzed by an E1 activating enzyme (SAE1/SAE2), an E2 conjugating enzyme (UBE2I), and E3 ligases such as PIAS proteins and TRIM28.
Can protein sumoylation be reversed?
Yes, SENP family proteases remove SUMO from target proteins, making sumoylation a reversible modification.
How can I study protein sumoylation in the lab?
Common methods include immunoblotting with anti-SUMO antibodies, mass spectrometry, co-immunoprecipitation, and CRISPR-based genetic screens.
What is the role of SUMOylation in cancer?
SUMOylation regulates oncoproteins and tumor suppressors, and targeting sumoylation is being explored as a cancer therapy.
What is the role of SUMOylation in viral infections?
SUMOylation of viral proteins, such as SARS-CoV-2 nucleocapsid, can enhance viral virulence, making sumoylation a potential antiviral target.
How does EDITGENE support sumoylation research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services for sumoylation studies.
Conclusion
Protein sumoylation (GO:0016925) is a critical post-translational modification that regulates a wide array of cellular processes and is implicated in major human diseases, including cancer, liver disease, and viral infections. Understanding its mechanisms and identifying specific substrates and regulators requires robust experimental models. CRISPR-based knockout, point mutation, knock-in, and overexpression cell models, combined with proteomics and screening approaches, are indispensable tools for dissecting sumoylation biology. EDITGENE offers comprehensive services to support these research efforts, from custom cell line generation to bioinformatics analysis.
References
- 1. Ren J et al.. 2024. TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence.. Nat Commun 15(1):244 PMID: 38172120
- 2. Yang Y et al.. 2024. Abnormal protein SUMOylation in liver disease: novel target for therapy.. J Mol Med (Berl) 102(6):719-731 PMID: 38565749
- 3. Sarge KD. 2016. Analysis of Protein Sumoylation.. Curr Protoc Protein Sci 83:14.8.1-14.8.8 PMID: 26836406
- 4. Dai X et al.. 2022. Ubiquitination and SUMOylation: protein homeostasis control over cancer.. Epigenomics 14(1):43-58 PMID: 34875856
- 5. Tan D et al.. 2023. SUMOylation of Rho-associated protein kinase 2 induces goblet cell metaplasia in allergic airways.. Nat Commun 14(1):3887 PMID: 37393345
- 6. Yang Y et al.. 2017. Protein SUMOylation modification and its associations with disease.. Open Biol 7(10) PMID: 29021212
- 7. Yang W et al.. 2024. Protein SUMOylation promotes cAMP-independent EPAC1 activation.. Cell Mol Life Sci 81(1):283 PMID: 38963422
- 8. Cox OF et al.. 2019. Developing Practical Therapeutic Strategies that Target Protein SUMOylation.. Curr Drug Targets 20(9):960-969 PMID: 30362419
